Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Optimizing CAR therapies with DART-AAV vector technology

Alexander Michels • 1 Apr 2022
ICLE 2022
General CAR-T

Alexander Michels, Paul-Ehrlich-Institut, Langen, Germany, discusses the role of DARPin-targeted adeno-associated virus (DART-AAV) vectors in the development of chimeric antigen receptor (CAR)-T cell therapies. Standard AAV vectors are unable to carry out selective transduction, and a majority of studies in the CAR therapies utilize synthetic and lentiviral vectors. The advent of DART-AAV vectors enables directed evolution of the vectors themselves and are flexible in targeting various cell types including CD8 cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

More from Alexander Michels

1:21
Comparing mouse models for the study of immunotherapies
Alexander Michels • 1 Apr 2022
1:57
Testing viral vectors for CAR therapies with in vivo models
Alexander Michels • 1 Apr 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals